Interestingly, inactivating mutations of IκBα have been detected preferentially in EBV-negative cases of HL (approximately 20% of cases; discussed in Section 5), suggesting that inactivation of IκBα is selected for as an alternative strategy to sustain NF-κB activation [194,197,201]. Here, NFKB1 is linked to Hodgkins lymphoma.